No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Dr. Woodrow Myers Joins the Freespira Board of Directors

Editor: What To Know

  • “Freespira’s breakthrough treatment for panic disorder and PTSD epitomizes the critical importance of innovation in healthcare – and the power of human-centered  technology to make a difference in the lives of those who struggle with debilitating mental illnesses on a daily basis,”.
  • In his current role, as managing director of Myers Ventures LLC, he has served as chief medical officer and chief healthcare strategist for Blue Cross Blue Shield of Arizona, CEO for Valitàs Health Services (Corizon Health), and a consultant to the $3 billion California Endowment, that state’s largest private health foundation.
  • Early in his medical career he worked as an emergency room physician and as a critical care intensivist and in both roles as a clinical teacher.

Freespira, Inc., maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced that Woodrow (Woody) Myers, MD, has joined the company’s Board of Directors.

Dr. Woodrow Myers is a nationally recognized leader in the development of healthcare quality initiatives and advanced healthcare management programs. He has over 40 years’ experience as a physician and clinical and business leader at some of the industry’s largest and most prestigious healthcare enterprises. In his current role, as managing director of Myers Ventures LLC, he has served as chief medical officer and chief healthcare strategist for Blue Cross Blue Shield of Arizona, CEO for Valitàs Health Services (Corizon Health), and a consultant to the $3 billion California Endowment, that state’s largest private health foundation.

“Freespira’s breakthrough treatment for panic disorder and PTSD epitomizes the critical importance of innovation in healthcare – and the power of human-centered  technology to make a difference in the lives of those who struggle with debilitating mental illnesses on a daily basis,” said Dr. Myers. “I’m excited to join Freespira’s Board of Directors to help the company continue to expand its already strong reach. Together, we can serve more of the millions of Americans who are suffering and desperately need access to new life-changing therapies.”

Freespira CEO Dean Sawyer commented, “We’re honored that Dr. Myers is joining our Board of Directors. Throughout his impressive career, he has proven to be deeply committed to improving healthcare by embracing innovation and technology, especially to support our nation’s underserved populations who deserve far better access to far better care. Most importantly, Dr. Myers brings not only invaluable knowledge and experience to the Board but also a strong passion for our mission of helping people to lead happier, healthier, symptom-free lives.”

Dr. Myers previously served as the executive vice president and chief medical officer of WellPoint, Inc., where he established the Healthcare Quality Assurance Division. Prior to that, he served as the director of healthcare management at the Ford Motor Company where he initiated quality assurance metrics for Ford healthcare vendors and established new global health and safety policies. Prior to Ford, he was corporate medical director for The Associated Group (now Anthem Blue Cross Blue Shield). He is also a former health commissioner for New York City and the state of Indiana.

He earned his medical degree (MD) from Harvard University, and a Master of Business Administration (MBA) from Stanford University. Early in his medical career he worked as an emergency room physician and as a critical care intensivist and in both roles as a clinical teacher.

The Freespira Board of Directors now includes the following members in addition to Dr. Myers and Mr. Sawyer: Executive chairman Russ Siegelman, a former Kleiner Perkins leader and current Stanford Business School lecturer; Ned Scheetz, founder and managing partner of Aphelion Capital; Jonathan MacQuitty, venture partner at Lightspeed Venture Partners; Steve Schwartz, executive vice president of mergers and acquisitions for Senior Connect Acquisition Corp.; and Debra Reisenthel, founding CEO of Freespira.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy